Alnylam Pharmaceuticals (ALNY) Stock Price, Quote, News & History | Benzinga

SPY771.23+0.28%QQQ723.43+0.81%BTC/USD83,076.34+1.51%DIA524.80+0.08%GLD378.00+0.09%TLT79.90−0.29%

Alnylam Pharmaceuticals Inc (ALNY) Stock Price, Quote, News & History

ALNYNASDAQ

Trade with Public

Trade with Public

$230.71

-2.58-1.11%

Last update: Oct 20, 4:32 PM

$230.71

-2.58-1.11%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$237.73

Close

$230.71

Volume / Avg.

1.51M / 1.71M

Day Range

$229.54 - $238.96

52 Wk Range

197.81 - 495.55

Market Cap

$30.87B

P/E Ratio

40.64

Dividend Yield

-

Exchange

NASDAQ

RSI

46

Short Interest

7.68%

Days to Cover

6.45

Recent Alnylam Pharmaceuticals, Inc. News

Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average

The Nasdaq 100 trades at records Monday, yet 55 of its 101 stocks sit below their 50-day average. QQQ has beaten equal-weight QQQE by 8% since late July.

Piero Cingari

Stock Market Today: S&P 500 Slips as Micron Fails to Impress, 10-Year Yields Ease to 5.25%

Micron slides despite a record quarter as the 10-year yield nears 5.3% and oil tops $92, while Accenture, Coherent and Vicor surge on earnings and AI optics.

Piero Cingari

Biotech Is Booming, But These 2 Stocks Missed the Memo

The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.

Erica Kollmann

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.

Avi Kapoor

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighed on expectations and investors reacted.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

911.81M

Investing Cash Flow (TTM)

74.94M

Financing Cash Flow (TTM)

-377.00M

Free Cash Flow (TTM)

819.87M

Capital Expenditure (TTM)

-91.95M

Net Change in Cash (TTM)

609.75M

Analyst Trends and Forecast

10

3

Jul

6

1

Aug

3

Sep

3

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$29.18B

PE Ratio (TTM)

40.64

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

6.74

PB Ratio (TTM)

23.05

Earnings Yield % (TTM)

2.46%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

26.40

Price / EBITDA (TTM)

29.28

Price / Free Cash Flow (TTM)

39.48

Book Value / Share

$10.12

Company Debt

Total Debt

$1.01B

LT Debt

$1.01B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$1.71B

Debt to Equity

0.94

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-